Mamoun Alhamadsheh, BPharm, PhD
Department of Pharmaceutics and Medicinal Chemistry
Phone: (209) 946-3164
Click here to learn more about Dr. Alhamadsheh's research lab.
At Pacific Since:
PhD, 2004, University of Toledo, Toledo, OH
BPharm, 1999, Jordan University of Science and Technology, Jordan
Stanford University, 2008-2011
Portland State University, 2004-2007
• Protein-protein interactions
• Amyloid beta aggregation in Alzheimer's disease
• Transthyretin Amyloidosis
Our laboratory employs an interdisciplinary approach to study protein-protein interactions (PPIs), combining synthetic organic chemistry with biochemistry and molecular biology. We are interested in developing small molecules that can be used to probe or inhibit PPIs. These small molecules would be used to understand the structure and function of multi-protein complexes as well as to develop new leads for drug discovery. Due to the urgent need for new drugs, we are particularly interested in developing chemical tools and therapeutic agents for protein aggregation (a type of PPIs) diseases such as Alzheimer's disease and Transthyretin Amyloidosis.
Click here to read more about his research and scholarly activities.
Mamoun Alhamadsheh, BPharm, PhD, had his paper "A biomimetic approach for enhancing the in vivo half-life of peptides" published in the Nature Chemical Biology Journal. Co-authors are Sravan C. Penchala '16, Mark R. Miller '17, Arindom Pal '19, Jin Dong '16, Nikhil R. Madadi '15, Jinghang Xie '14, Hyun Joo (Chemistry), Jerry Tsai (Chemistry), Patrick Batoon '16 (Chemistry), Vyacheslav Samoshin (Chemistry), Andreas Franz (Chemistry), Trever Cox '14, Jesse Miles '15, William K. Chan, PharmD, PhD, Professor of Pharmaceutics and Medicinal Chemistry and Miki S. Park, PhD, Associate Professor of Pharmaceutics and Medicinal Chemistry. Click here to read more.
Penchala SC, Connelly S, Wang Y, Park MS, Zhao L, Baranczak A, Rappley I, Vogel H, Liedtke M, Witteles RM, Powers ET, Reixach N, Chan WK, Wilson IA, Kelly JW, Graef IA, Alhamadsheh MM. AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin. Proc. Natl. Acad. Sci. USA. 2013;110:9992-9997.
Mamoun Alhamadsheh had his article "Potent Kinetic Stabilizers That Prevent Transthyretin-Mediated Cardiomyocyte Proteotoxicity" published and featured on the cover in Science Translational Medicine magazine. It was also mentioned in Chemical & Engineering News, published by the American Chemical Society, and The Alzheimer Research Forum.